|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Imielinski M, Berger AH, Hammerman PS,
Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M,
Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma
with massively parallel sequencing. Cell. 150:1107–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roberts PJ and Stinchcombe TE: KRAS
mutation: Should we test for it, and does it matter. J Clin Oncol.
31:1112–1121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bergethon K, Shaw AT, Ou SH, Katayama R,
Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang
R, et al: ROS1 rearrangements define a unique molecular class of
lung cancers. J Clin Oncol. 30:863–870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu K, Zhang X, Li F, Xiao D, Hou Y, Zhu S,
Liu D, Ye X, Ye M, Yang J, et al: Frequent alterations in
cytoskeleton remodelling genes in primary and metastatic lung
adenocarcinomas. Nat Commun. 6:101312015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Inuzuka M, Hayakawa M and Ingi T: Serinc,
an activity-regulated protein family, incorporates serine into
membrane lipid synthesis. J Biol Chem. 280:35776–35783. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Digumarti R, Bapsy PP, Suresh AV,
Bhattacharyya GS, Dasappa L, Shan JS and Gerber DE: Bavituximab
plus paclitaxel and carboplatin for the treatment of advanced
non-small-cell lung cancer. Lung Cancer. 86:231–236. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin Y, Huang X, Lynn KD and Thorpe PE:
Phosphatidylserine-targeting antibody induces M1 macrophage
polarization and promotes myeloid-derived suppressor cell
differentiation. Cancer Immunol Res. 1:256–268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bondanza A, Zimmermann VS, Rouvere-Querini
P, Turnay J, Dumitriu IE, Stach CM, Voll RE, Gaipl US, Bertling W,
Pöschl E, et al: Inhibition of phosphatidylserine recognition
heightens the immunogenicity of irradiated lymphoma cells in vivo.
J Exp Med. 200:1157–1165. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kok JW and Sietsma H: Sphingolipid
metabolism enzymes as targets for anticancer therapy. Curr Drug
Targets. 5:375–382. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Proia RL and Hla T: Emerging biology of
sphingosine-1-phosphate: Its role in pathogenesis and therapy. J
Clin Invest. 125:1379–1387. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ogretmen B and Hannun YA: Biologically
active sphingolipids in cancer pathogenesis and treatment. Nat Rev
Cancer. 4:604–616. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ren WH, Yang CY, Yang XM and Yu L:
siRNA-mediated knockdown of hTDE2 retards cell cycle progression
through transcriptional activation of p21. Oncol Rep. 31:1314–1322.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Player A, Gillespie J, Fujii T, Fukuoka J,
Dracheva T, Meerzaman D, Hong KM, Curran J, Attoh G, Travis W and
Jen J: Identification of TDE2 gene and its expression in non-small
cell lung cancer. Int J Cancer. 107:238–243. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Selamat SA, Chung BS, Girard L, Zhang W,
Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, et al:
Genome-scale analysis of DNA methylation in lung adenocarcinoma and
integration with mRNA expression. Genome Res. 22:1197–1211. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Okayama H, Kohno T, Ishii Y, Shimada Y,
Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S,
et al: Identification of genes upregulated in ALK-positive and
EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res.
72:100–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens
JA, Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS One.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
NCI-H1650 [H-1650, H1650]
(ATCC® CRL-5883™). https://www.atcc.org/~/ps/CRL-5883.ashx
|
|
24
|
NCI-Navy Medical Oncology Branch cell line
supplement. J Cell Biochem Suppl. 24:1–291. 1996.
|
|
25
|
Sexton DW, Blaylock MG and Walsh GM: Human
alveolar epithelial cells engulf apoptotic eosinophils by means of
integrin- and phosphatidylserine receptor-dependent mechanisms: A
process upregulated by dexamethasone. J Allergy Clin Immunol.
108:962–969. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boussat S, Eddahibi S, Coste A, Fataccioli
V, Gouge M, Housset B, Adnot S and Maitre B: Expression and
regulation of vascular endothelial growth factor in human pulmonary
epithelial cells. Am J Physiol Lung Cell Mol Physiol.
279:L371–L378. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimano H: Sterol regulatory
element-binding proteins (SREBPs): Transcriptional regulators of
lipid synthetic genes. Prog Lipid Res. 40:439–452. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakakuki M, Shimano H, Inoue N, Tamura M,
Matsuzaka T, Nakagawa Y, Yahagi N, Toyoshima H, Sato R and Yamada
N: A transcription factor of lipid synthesis, sterol regulatory
element-binding protein (SREBP)-1a causes G(1) cell-cycle arrest
after accumulation of cyclin-dependent kinase (cdk) inhibitors.
FEBS J. 274:4440–4452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Streicher R, Kotzka J, Muller-Wieland D,
Siemeister G, Munck M, Avci H and Krone W: SREBP-1 mediates
activation of the low density lipoprotein receptor promoter by
insulin and insulin-like growth factor-I. J Biol Chem.
271:7128–7133. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bedard PL, Tabernero J, Janku F, Wainberg
ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Pérez-García J,
Stathis A, Britten CD, et al: A phase Ib dose-escalation study of
the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with
the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with
selected advanced solid tumors. Clin Cancer Res. 21:730–738. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang BX, Akbar M, Kevala K and Kim HY:
Phosphatidylserine is a critical modulator for Akt activation. J
Cell Biol. 192:979–992. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang W, Liu J, Hu X, Li P, Leak RK, Gao Y
and Chen J: n-3 polyunsaturated fatty acids reduce neonatal
hypoxic/ischemic brain injury by promoting phosphatidylserine
formation and Akt signaling. Stroke. 46:2943–2950. 2015. View Article : Google Scholar : PubMed/NCBI
|
